{
  "compound": "Marijuana/cannabinoids",
  "condition": "GLAUCOMA",
  "effect_size": "N/A (guideline)",
  "study_type": "CLINICAL_GUIDELINE",
  "source": "NORML:GLAUCOMA_GUIDELINE_001",
  "participants": "Evidence-based position statement",
  "year": 2014,
  "notes": "American Academy of Ophthalmology Position on Marijuana for Glaucoma",
  "confidence": "medium",
  "abstract": "Acknowledges IOP-lowering effect; Not recommended as first-line due to: short duration (3-4h), systemic side effects, need for frequent dosing; Conventional therapies preferred"
}